[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100501402":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":50,"responsibleParty":63,"collaborators":66,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":48,"enrollmentInfo":79,"targetDuration":48,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":95,"whyStopped":48,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Amsterdam UMC, location VUmc","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Minimally invasive pulmonary metastasectomy","ACTIVE_COMPARATOR","Minimally invasive parenchymal sparing pulmonary metastasectomy Surgical approach by means of video-assisted thoracic surgery (VATS), robot-assisted (RATS), or uniportal VATS",[13],"Procedure: Minimally invasive pulmonary metastasectomy",{"label":15,"type":16,"description":17,"interventionNames":18},"Stereotactic ablative radiotherapy","EXPERIMENTAL","Gross tumor volume = tumor visible on CT (+\u002F- PET) No CTV margin will be added (Clinical target volume (CTV) = Gross target volume (GTV)) Planning Target Volume (PTV): GTV plus margins of 3-5mm (varying depending on site, motion, SABR delivery approach)",[19],"Radiation: Stereotactic ablative radiotherapy",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Surgical margin is equal to tumor size, if possible The goal is a parenchymal-sparing resection",[9],[26],"Lung metastasectomy",{"type":28,"name":15,"description":29,"armGroupLabels":30,"otherNames":31},"RADIATION","Depending on tumor location, 54 Gy in 3 fractions, 55 Gy in 5 fractions, 60 Gy in 8 fractions.",[15],[32,33],"SABR","Stereotactic body radiation therapy (SBRT)",[35],{"name":36,"affiliation":37,"role":38},"Martijn van Dorp, MD","AUMC","PRINCIPAL_INVESTIGATOR",[40,45],{"name":36,"role":41,"phone":42,"phoneExt":43,"email":44},"CONTACT","+31 20 444 4444","61647","m.vandorp@amsterdamumc.nl",{"name":46,"role":41,"phone":47,"phoneExt":48,"email":49},"Simone Gooijer, MD","+31 20 444 4782",null,"sa.gooijer@nwz.nl",[51],{"facility":52,"status":48,"city":53,"state":48,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":48},"Amsterdam University Medical Center (AUMC)","Amsterdam","1081 HZ","Netherlands","NL",{"type":58,"coordinates":59},"Point",[60,61],4.88969,52.37403,{"lat":61,"lon":60},{"type":38,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":48,"oldOrganization":48},"Martijn van Dorp","Principal Investigator",[67],{"name":68,"class":6},"Dutch Cancer Society","100501402","colorectal-pulmonary-metastases-pulmonary-metastasectomy-versus-stereotactic-ablative-radiotherapy-100501402",false,"NCT05808790","Colorectal Pulmonary Metastases: Pulmonary Metastasectomy Versus Stereotactic Ablative Radiotherapy","Colorectal Pulmonary Metastases: Pulmonary Metastasectomy Versus Stereotactic Ablative Radiotherapy: a Phase III Multicenter Randomized Controlled Trial","COPPER","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG)-Performance status 0 - 2\n* Willing to provide informed consent\n* Patients with 1 to 3 lung metastases from colorectal cancer eligible for both a minimally invasive surgical resection and SABR, as assessed by the multidisciplinary tumor board (MDT)\n* Radically treated primary colorectal cancer\n* Patient is able and willing to complete the quality-of-life questionnaires\n* Previous liver metastases are radically treated with curative intent\n* Histologically confirmed malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.\n\nExclusion Criteria:\n\n* Previous or present metastases outside liver or lungs\n* Concurrent malignant cancer, or history of other malignant cancers within the past 5 years (excluding prespecified low-risk cancers)\n* Hilar or mediastinal lymph node metastases\n* Poor cardiopulmonary function test\n* Inability to treat all colorectal metastases\n* Surgical resection by means of a bilobectomy or pneumonectomy","ALL","18 Years",{"count":80,"type":81},394,"ESTIMATED","INTERVENTIONAL",[84],"NA","COPPER is an international, multicenter, parallel-arm, phase III randomized controlled trial comparing two local treatment strategies (SABR or metastasectomy) for patients with an indication for local treatment for limited (max. three) colorectal pulmonary metastases",[87,88],"Lung Metastases","Colorectal Cancer Metastatic",[90,91,92,93,94],"Colorectal pulmonary metastases","Pulmonary metastasectomy","Stereotactic radiotherapy","Randomized controlled trial","Colorectal cancer metastases","NOT_YET_RECRUITING","2023-04-10",{"date":98,"type":99},"2023-04-11","ACTUAL",{"date":101,"type":81},"2024-01-01",{"date":103,"type":81},"2030-12-31",{"name":5,"class":6},1]